Abstract
Objective: Describe the clinical case of a patient admitted to the Internal Medicine service of a tertiary hospital, diagnosed with Primary Hyperoxaluria, who developed renal, cardiac, intestinal, and hematological complications. Case details: A 35-year-old male patient was admitted to the Medical Clinic ward in 2021 for investigation of severe anemia, resistant to erythropoietin administration, associated with hepatosplenomegaly. He presented with complaints of asthenia, low back pain, and limitation of movement in the lower limbs. Admission laboratory results indicated anemia, renal insufficiency, hyperkalemia, and hypercalcemia. Abdominal CT showed diffuse renal calcification, calcification of the abdominal wall and iliac vessels, and bone marrow infiltration. A bone marrow biopsy confirmed infiltration by calcium oxalate. In 2023, a genetic test confirmed primary hyperoxaluria. Final considerations: The interaction between chronic kidney disease, complications associated with the formation of kidney stones, and oxalate overload in organs highlights the importance of a multidisciplinary approach for proper diagnosis and treatment. Genetic follow-up, therapeutic management, and, in severe cases, transplant intervention are essential for the management of this challenging condition.
References
ALMEIDA JB, et al. Oxalose primária diagnosticada após transplante renal – relato de caso. Braz J Transplant, 2007; 10(3): 779-781.
COCHAT P, et al. Primary hyperoxaluria: clinical aspects and management. Nephrology Dialysis Transplantation, 2008; 23(9): 2639-2648.
GAGNON RF, et al. Bone and joint manifestations of primary hyperoxaluria. Osteoporosis International, 2017; 28(9): 2751-2759.
HOPPE B, et al. Primary hyperoxaluria: diagnosis and management. Pediatric Nephrology, 2012; 27(8): 1243-1251.
KNIGHT JA, THAKKER RV. Primary hyperoxaluria: pathophysiology, diagnosis and management. Nature Reviews Nephrology, 2015; 11(10): 629-639.
KÖLLER M, et al. Lumasiran for primary hyperoxaluria type 1: efficacy and safety results of a phase 3 trial. The Lancet, 2022; 399(10337): 1724-1734.
KOLLING G, et al. Diagnosis and management of primary hyperoxaluria. Journal of Clinical Nephrology, 2020; 4(1): 65-77.
LAU W, et al. Oxalate deposition in cardiac tissues and its impact on heart function in patients with primary hyperoxaluria. Nephrology Dialysis Transplantation, 2019; 34(3): 439-448.
LORENZO V, et al. Hiperoxaluria primaria. Nefrologia, 2014; 34(3): 398-412.
MANDRILE G, et al. Primary hyperoxaluria in Italy: the past 30 years and the near future of a (not so) rare disease. Journal of Nephrology, 2022; 35(3): 841-850.
MCCULLOCH M, HO GY. Liver and kidney transplantation for primary hyperoxaluria: a review of the literature. Transplant Proceedings, 2017; 49(10): 2194-2199.
MILLER LS, et al. Hemolysis and its role in the pathophysiology of primary hyperoxaluria. Journal of Nephrology, 2014; 27(2): 153-161.
MILLINER DS, THUNSTRÖM M. Genetic mutations in primary hyperoxaluria and their impact on treatment. Journal of the American Society of Nephrology, 2005; 16(6): 1681-1687.
MOECKEL GW, et al. Primary hyperoxaluria type 1: pathophysiology, diagnosis, and management. Seminars in Nephrology, 2013; 33(5): 545-552.
MUCHA L, et al. Clinical and economic impact of primary hyperoxaluria: a retrospective claims analysis. Journal of Managed Care & Specialty Pharmacy, 2022; 28(3): 316-323.
PATIÑO L, et al. Hiperoxaluria primaria tipo 1. Acta Medica Colombiana, 2018; 43(1S): 40-41.
POH Z, et al. Cardiovascular manifestations of primary hyperoxaluria: a review. European Heart Journal, 2021; 42(15): 1532-1540.
RIOS JFN, et al. Hiperoxalúria primária diagnosticada após transplante renal: relato de dois casos e revisão da literatura. Brazilian Journal of Nephrology, 2017; 39: 462-466.
SANTOS P, et al. Gastrointestinal manifestations of primary hyperoxaluria: the role of oxalate deposition in the digestive tract. Journal of Clinical Gastroenterology, 2018; 52(4): 339-346.
TSIMIHODIMOS V, et al. The prognosis of patients with primary hyperoxaluria type 1: multisystem involvement and high mortality. Nephrology Dialysis Transplantation, 2016; 31(4): 577-584.
